ReviewFrontiers in aging neuroscience2016
Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma.
Review in Frontiers in aging neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Trial
- Impact of Oral Citicoline, Antioxidant Vitamins, and Blackcurrant Supplementation on Primary Open-Angle Glaucoma: An OCT and OCTA Study.Biomedicines · 2025Article
- Randomized, Cross over, Multicenter, Single-Blind Study Comparing Citicoline 500 mg/Homotaurine 50 mg/Vitamin B3 54 mg/Pyrroloquinoline Quinone 5 mg (Neuprozin MitoJournal of clinical medicine · 2025Article
- Neuroprotective Effect of the Combination of Citicoline and CoQ10 in a Mouse Model of Ocular Hypertension.Antioxidants (Basel, Switzerland) · 2024Article
- Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma.Frontiers in medicine · 2023Article
- Role of Citicoline in Patients With Mild Cognitive Impairment.Neuroscience insights · 2023Review
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.Journal of personalized medicine · 2022Review
- Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma.Frontiers in medicine · 2022Review
- Article
- [The role of citicoline in glaucoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2021Article
- New perspectives of immunomodulation and neuroprotection in glaucoma.Central-European journal of immunology · 2021Review
- Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma.Nutrients · 2020Review
- Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment.Journal of ophthalmology · 2020Review
- Cholinergic nervous system and glaucoma: From basic science to clinical applications.Progress in retinal and eye research · 2019Review
- Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution.PloS one · 2019Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral form of citicoline, a nootropic and neuroprotective drug in use for almost five decades, recently was pronounced a food supplement in both USA and EU. The idea of adding citicoline to topical treatment of primary open angle glaucoma (POAG) aimed at decreasing intraocular pressure (IOP) appeared as a logical consequence of accepting neurodegenerative character of this disease. Experimental data, and also few clinical studies indicate that this substance has potential to counteract some important pathological mechanisms which seem to contribute to POAG initiation and progression, such as excitotoxicity and oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.